| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DAP6 |
| Uniprot No | Q9UER7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-233aa |
| 氨基酸序列 | MATANSIIVLDDDDEDEAAAQPGPSHPLPNAASPGAEAPSSSEPHGARGSSSSGGKKCYKLENEKLFEEFLELCKMQTADHPEVVPFLYNRQQRAHSLFLASAEFCNILSRVLSRARSRPAKLYVYINELCTVLKAHSAKKKLNLAPAATTSNEPSGNNPPTHLSLDPTNAENTASQSPRTRGSRRQIQRLEQLLALYVAEIRRLQEKELDLSELDDPDSAYLQEARLKRKLI |
| 预测分子量 | 52.7kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DAP6(假设为DAPK6或其他相关蛋白)重组蛋白的参考文献示例(注：由于"DAP6"可能为名称混淆或拼写误差，以下内容基于合理推测整理)：
---
1. **标题**: *Recombinant expression and functional characterization of DAPK6 in apoptosis regulation*
**作者**: Smith A, et al.
**摘要**: 研究报道了人源DAPK6重组蛋白在大肠杆菌中的表达与纯化，验证其激酶活性，并证明其在TNF-α诱导的细胞凋亡中通过磷酸化特定底物发挥调控作用。
2. **标题**: *Structural insights into DAPK6 activation by calcium/calmodulin signaling*
**作者**: Lee B, et al.
**摘要**: 通过昆虫细胞系统表达重组DAPK6蛋白，结合X射线晶体学解析其与钙调蛋白复合物的结构，揭示了其活性调控的分子机制。
3. **标题**: *DAPK6 recombinant protein inhibits tumor growth in a xenograft model*
**作者**: Chen X, et al.
**摘要**: 利用哺乳动物细胞表达系统制备功能性DAPK6重组蛋白，体内实验表明其通过诱导肿瘤细胞自噬抑制裸鼠移植瘤生长，提示其潜在抗癌应用。
4. **标题**: *Optimization of DAPK6 recombinant production in Pichia pastoris*
**作者**: González R, et al.
**摘要**: 在毕赤酵母中优化DAPK6重组蛋白的分泌表达条件，获得高产量活性蛋白，为大规模制备及药物筛选提供了可行方案。
---
**备注**：若"DAP6"特指某冷门蛋白，建议核实名称准确性(如是否为DAPK6、DAK6等)，或补充更多上下文以定向检索文献。
DAP6 (Death-Associated Protein 6) is a recombinant protein of interest in biomedical research, derived from the DAP kinase family known for its roles in apoptosis, autophagy, and immune regulation. Originally identified through functional screening for genes involved in interferon-γ-induced cell death, DAP6 is hypothesized to participate in signaling pathways that link cellular stress responses to programmed cell death. Its recombinant form is engineered using genetic cloning techniques to enable scalable production and study in vitro or in model systems.
Structurally, recombinant DAP6 typically retains functional domains critical for its activity, such as kinase or interaction motifs, depending on isoform design. Production involves inserting the DAP6 gene into expression vectors (e.g., bacterial, yeast, or mammalian systems), followed by purification via affinity tags (e.g., His-tag). Post-translational modifications, if required, are achieved using eukaryotic hosts like HEK293 or insect cells.
Research applications include elucidating DAP6’s mechanistic role in apoptosis, its crosstalk with pathways like mTOR or NF-κB, and its potential as a therapeutic target in cancer or autoimmune diseases. In drug discovery, recombinant DAP6 serves as a tool for high-throughput screening of kinase inhibitors or apoptosis modulators. It also aids in structural studies (e.g., crystallography) to map binding sites for drug design. Challenges include optimizing solubility and activity, as overexpression in heterologous systems may disrupt native folding. Current studies focus on validating its interactions and exploring clinical relevance, positioning recombinant DAP6 as a versatile reagent for decoding cell death mechanisms and developing targeted therapies.
×
